אנברל - Enbrel

מתוך ויקיתרופות
גרסה מתאריך 12:35, 26 בספטמבר 2016 מאת דנה לוי (שיחה | תרומות)

(הבדל) → הגרסה הקודמת | הגרסה האחרונה (הבדל) | הגרסה הבאה ← (הבדל)
קפיצה אל: ניווט, חיפוש
Banner.jpg
נתוני תרופה
במרשם RxIcon.png
מינונים נוספים
קבוצה פרמקולוגית (ATC4)

L04AB
Tumor necrosis factor alpha (TNF-α) inhibitors

מרכיב פעיל (ATC5) *Etanercept 25 MG/VIAL ‏L04AB01
  • Etanercept 25 MG/VIAL ‏L04AB01
  • Tumor necrosis factor alpha (tnf-a) inhibitors L04AB ‏L04AB01
  • 5010981001809 לא ‏L04AB01
  • Birkendorfer strasse 65, D-88397 BIBERACH AN DER RISS, GERMANY bulk ‏L04AB01
  • Grange castle business park, clondalkin, dublin 22, IRELAND release and stability testing of the drug substance and drug product , manufacture of drug substance ‏L04AB01
  • Rijksweg 12 , B-2870 PUURS, BELGIUM manufacture of drug product and quality control testing of drug product with the exception of Apoptosis Bioassay and Receptor Binding Assay ‏L04AB01
  • Schuetzenstrasse 87 D-88212 RAVENSBURG,GERMANY manufacturer of diluent syringe , stability testing of diluents syringe , release testing of diluent syringe , visual inspection of diluent syringe ‏L04AB01
  • Holbeinstrasse 40, D-88212 RAVENSBURG, GERMANY stability testing of diluents syringe , visual inspection of diluent syringe ‏L04AB01
  • Helmut - vetter - st. 10, 88213 RAVENSBURG, GERMANY visual inspection of diluent syringe ‏L04AB01
  • Eisenbahnstrasse 2 - 4 , 88085 LANGENARGEN, GERMANY stability testing of diluents syringe , release testing of diluent syringe , visual inspection of diluent syringe , assembly of V-OVS 10.6 closure system , preparation of stoppers ‏L04AB01
  • Mooswiesen 2, D - 88214 RAVENSBURG, GERMANY visual inspection of diluent syringe ‏L04AB01
  • New lane, havant, hampsire, p09 2NG, UK packaging , labelling , final release ‏L04AB01
  • Etanercept 25 MG/VIAL ‏L04AB01
צורת מתן S.C
צורת מינון LYOPHILIZED POWDER FOR INJECTION
התוויה
* Rheumatoid arthritis:Enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate.. Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.* Polyarticular juvenile idiopathic arthritis: Treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Enbrel has not been studied in children aged less than 2 years.* Psoriatic arthritisTreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease.* Ankylosing spondylitisTreatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. * Plaque psoriasis Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* Paediatric plaque psoriasis Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* Juvenile idiopathic arthritisTreatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.*Axial spondyloarthritis*Ankylosing spondylitis(AS)Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.*Non-radiographic axial spondyloarthritisTreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs)

נתוני סל [ הצגה ]

הגבלות הסל
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
התוויה בסל
שימוש בסל
תאריך הכללה בסל
01/03/2002
מסגרת הכללה בסל
תופעות לוואי
שימוש בהריון והנקה
עלון לרופא
*עלון לצרכן אנברל ® במאגר משרד הבריאות
ערכים בוויקירפואה ערכים קשורים בוויקירפואה
חיפוש מאמרים מאמרים ב-PubMed
מידע ברשת RxList WebMD Drugs.com
שם יצרן WYETH PHARMACEUTICALS LIMITED, U.K.
שם בעל הרישום PFIZER PHARMACEUTICALS ISRAEL LTD
רישיון תאריך הגשה: 02/2003. רישיון מתאריך: 08/2013


תאריך עדכון: 14/05/19


אנברל - Enbrel true